News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibe Therapeutics Inc. Announces First Human Dose Of ATB-346 In Phase I Clinical Trial



6/27/2014 9:57:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) announced today that following the receipt of a No Objection Letter from Health Canada last week, its Phase I clinical trial was initiated today. This first clinical study of ATB-346, a drug with the promise of being a safer, anti-inflammatory painkiller, involves safety and pharmacokinetic evaluations in healthy human subjects and will be conducted in Montreal, Canada over the coming months.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES